Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Last updated: September 3, 2026 TScan Therapeutics cut approximately 75% of its staff on September 2, 2026 to pivot to in vivo TCR T therapy,
Last updated: September 2, 2026 Novartis paused eight autoimmune trials of its CD19 CAR T therapy after three patient deaths, Bristol Myers Squibb paused its
Last updated: September 1, 2026 The White House announced most favored nation pricing agreements with nine more drugmakers on August 31, 2026: Alcon, Astellas, BeOne,
Last updated: August 31, 2026 On Friday, August 28, 2026, five scheduled life sciences catalysts arrived as promised: FDA approvals for Takeda’s Mimrylo and Roivant’s
Last updated: August 28, 2026 Boston Scientific disclosed a cyberattack that has disrupted global ordering and shipping, Tezspire met every endpoint in its Phase 3
Last updated: August 27, 2026 The FDA approved Revolution Medicines’ Rasonque (daraxonrasib) on August 26, the first broad RAS targeted medicine in metastatic pancreatic cancer,
Last updated: August 26, 2026. ARCH and Population Health Partners launched Sentivera with a Haisco type 2 inflammation license worth $75.89 million upfront and up to $1.46 billion in milestones, while 25 biotech IPOs priced in 2026 have a Leerink banker calling the market close to escape velocity. This page covers the Sentivera deal structure, the IPO window’s quality bar, the Amylyx closing watch, the UK oral obesity launch, Cellares layoffs, and the Medicare litigation rulings.
Last updated: August 25, 2026 The FDA moved Capricor’s deramiocel decision to November 22, 2026 after classifying new HOPE-3 extension data as a major amendment,
Last updated: August 24, 2026 Capricor’s August 22, 2026 PDUFA target action date for deramiocel passed with no public FDA action and no company statement.
Last updated: August 21, 2026 Amylyx priced an upsized $500.2 million stock offering at $35.50 per share within two days of its avexitide Phase 3
